Structured evidence table for Algal Omega-3 Lipid Profile Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Algal Omega-3 Lipid Profile Randomized Trial | Despite strong biological plausibility, clinical evidence remains heterogeneous. | 4 | Egalini F (2026) | Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. |
| Algal Omega-3 Lipid Profile Randomized Trial | While traditional low-dose mixed formulations often failed to show significant benefits, high-dose purified EPA (icosapent ethyl, 4 g/day) has demonstrated a substantial reduction in residual cardiovascular risk in specific populations. | 4 | Egalini F (2026) | Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. |
| Algal Omega-3 Lipid Profile Randomized Trial | However, this clinical success is accompanied by a modest but consistent increase in atrial fibrillation risk at pharmacological doses, suggesting a need for better risk stratification. | 4 | Egalini F (2026) | Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. |
| Algal Omega-3 Lipid Profile Randomized Trial | Omega-3 polyunsaturated fatty acids (ω-3 PUFAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are critical modulators of cardiovascular physiology, acting through anti-inflammatory signaling, membrane remodeling, and transcriptional regulation. | 4 | Egalini F (2026) | Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. |
| Algal Omega-3 Lipid Profile Randomized Trial | As a result, an expanding number of dietary supplements and specialty oils are marketed under a common omega-7 claim. | 4 | Correa Mona (2026) | Palmitoleic acid content and composition-based nutritional quality of commercial omega-7 oils and supplements |
| Algal Omega-3 Lipid Profile Randomized Trial | In human nutrition studies, macadamia nuts-containing diets and foods have generally improved total and LDL-cholesterol when they replace more saturated fat sources (), although not all comparisons with oleic acid have shown favorable outcomes (). | 4 | Correa Mona (2026) | Palmitoleic acid content and composition-based nutritional quality of commercial omega-7 oils and supplements |
| Algal Omega-3 Lipid Profile Randomized Trial | Other FA includes minor and unusual fatty acids; in FOEE samples, specific fatty acids include 16:2 n-4 and 16:3 n-4 acids as well as other minor fatty acids typically found in fish oil (see). | 4 | Correa Mona (2026) | Palmitoleic acid content and composition-based nutritional quality of commercial omega-7 oils and supplements |
| Algal Omega-3 Lipid Profile Randomized Trial | 1 2–4 2–8 23 3–9 cis Palmitoleic acid (POA; 16:1 n-7) is a monounsaturated omega-7 fatty acid that has attracted growing interest since POA was proposed to act as a lipokine linking adipose tissue to systemic metabolism (). | 4 | Correa Mona (2026) | Palmitoleic acid content and composition-based nutritional quality of commercial omega-7 oils and supplements |
Source documents